Moderna, Inc. Common Stock MRNA

Moderna, Inc. se dedica a medicamentos transformadores basados en ácido ribonucleico mensajero (ARNm). Ha creado una plataforma para mejorar las propiedades farmacéuticas subyacentes de nuestros medicamentos de ARNm. Su plataforma consta de tres áreas: tecnologías de ARNm, tecnologías de entrega y procesos de fabricación. Está investigando la ciencia del ARNm para minimizar la activación no deseada del sistema inmunológico por el ARNm y maximizar la potencia del ARNm una vez en las células objetivo. Ha avanzado en paralelo en un diverso pipeline de desarrollo de 21 programas, de los cuales 10 han ingresado a estudios clínicos y otros tres tienen INDs abiertos. Sus programas de desarrollo de terapéutica y vacunas abarcan enfermedades infecciosas, oncología, enfermedades cardiovasculares y enfermedades genéticas raras. Ha creado seis modalidades: vacunas profilácticas, vacunas contra el cáncer, inmunoterapia intratumoral, terapéuticas regenerativas localizadas, terapéuticas secretadas sistémicas y terapéuticas intracelulares sistémicas.

• GlobeNewswire Inc. 1 oct

  Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026

  Nasdaq announced that Moderna, Inc. (MRNA) will replace Warner Bros. Discovery, Inc. (WBD) as a component of the Nasdaq-100 Index effective October 9, 2026. The Nasdaq-100 Index tracks 100 of the largest Nasdaq-listed non-financial companies and is tracked by over 200 investment products with $800 billion in assets under management globally.

  

• Zacks Investment Research 1 oct

  Moderna (MRNA) Stock Dips While Market Gains: Key Facts

  Moderna (MRNA) closed at $188.94, down 1.89% in the latest session, underperforming the S&P 500. Despite a strong monthly gain of 27.69%, the company faces headwinds with projected earnings of -$1.36 per share (down 166.67% YoY) and quarterly revenue expected at $888.78 million (down 12.52%). The stock holds a Zacks Rank #3 (Hold) rating with unchanged consensus estimates over the past 30 days.

  

• The Motley Fool 30 sept

  Prediction: Moderna Stock Will Soar 100% by 2030

  Moderna has rebounded from pandemic-era lows with a diversified product portfolio including COVID, RSV, and flu vaccines, plus promising oncology pipeline candidates. The analyst predicts 100% stock appreciation by 2030 based on potential revenue growth to ~$3 billion and positive pipeline data, though acknowledges manufacturing challenges for personalized cancer vaccines and current high valuation multiples.

  

• The Motley Fool 30 sept

  Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron Earnings

  U.S. markets rose midday on September 30, 2026, following softer-than-expected August PCE inflation data (3.4% year-over-year), which reduced expectations for an October rate hike. The Nasdaq Composite led gains at +0.99%, while the S&P 500 and Dow Jones showed more modest gains. However, analysts warn of concentration risk in AI stocks and deteriorating market breadth, with single-stock volatility rising despite major indexes near all-time highs.

  

• Zacks Investment Research 30 sept

  Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

  Both Moderna and BioNTech are transitioning beyond COVID-19 vaccines into oncology and other therapeutic areas. Moderna has already commercialized RSV and flu vaccines with positive intismeran cancer therapy results, while BioNTech relies more heavily on Comirnaty and has a broader but less advanced oncology pipeline. Moderna is rated as the better investment choice despite trading at a premium valuation, given its further-along transition away from COVID-19 dependency.